QUARTERLY CONDENSED FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A.

FOR THE PERIOD FROM 01 JANUARY 2013 TO 30 SEPTEMBER 2013

QUARTERLY CONDENSED FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. FOR THE PERIOD FROM 01 JANUARY TO 30 SEPTEMBER 2013 (All amounts are stated in PLN'000 unless otherwise indicated)

Table of contents

- A. SELECTED FINANCIAL DATA
- **B. QUARTERLY CONDENSED FINANCIAL STATEMENTS**

(All amounts are stated in PLN'000 unless otherwise indicated)

A. SELECTED FINANCIAL DATA

PLN'000

Description	01.01-30.09.2013	01.01-30.09.2012
Description	01.01 00.03.2010	01.01 00.03.2012

	PLN	EUR	PLN	EUR			
PROFIT AND LOSS ACCOUNT							
Net revenues from sales of products, goods and materials	147,451	34,764	134,526	32,070			
Costs of sales	136,886	32,273	129,843	30,953			
Operating profit (loss)	2,066	487	-4,955	-1,181			
Profit (loss) before tax	195	46	-6,740	-1,607			
Net profit (loss)	-90	-21	-5,827	-1,389			
Number of shares	23,566,900	23,566,900	23,566,900	23,566,900			
Net profit (loss) per share (PLN/EUR)	-0.0038	-0.0009	-0.25	-0.06			

30.09.2013 30.09.2012

BALANCE SHEET				
Non-current assets	94,862	22,499	105,960	25,757
Current assets	16,195	3,841	16,195	3,937
Equity	44,071	10,453	47,164	11,465
Liabilities and provisions for liabilities	66,986	15,887	74,991	18,229
Book value per share (PLN/EUR)	1.87	0.44	2.00	0.49

CASH FLOW STATEMENT				
Net cash flows from operating activities	11,219	2,645	5,995	1,429
Net cash flows from investing activities	-1,870	-441	-13,899	-3,313
Net cash flows from financial activities	-8,601	-2,028	4,072	971

PLN/EUR exchange rate	2013	2012
- balance sheet data	4.2163	4.1138
- profit and loss account data	4.2415	4.1948

The average exchange rate announced by the National Bank of Poland as at the balance sheet date was used to translate the balance sheet data.

The exchange rate equal the arithmetic mean of exchange rates announced by the National Bank of Poland as at the last day of particular months during the period was used to translate profit and loss account items and cash flow statement items.

(All amounts are stated in PLN'000 unless otherwise indicated)

B. INTRODUCTION TO THE QUARTERLY CONDENSED FINANCIAL STATEMENT

1. DETAILS OF THE COMPANY

Centrum Medyczne Enel-Med was established based on the notarial deed drawn up on 22 December 2006, Repertory A no. 5930/2006 under the name of Centrum Medyczne Enel-Med Spółka Akcyjna (Enel-Med Medical Centre Joint-Stock Company).

On 28 February 2007, the Company was entered into the National Court Register under number KRS 0000275255.

The Company's registered office is located in Warsaw, at ul. Słomińskiego 19, apt. 524.

The Company was assigned Statistical Identification Number (REGON) 140802685.

The core business of the Company includes:

- general medical practice activities (PKD 8621Z);
- specialist medical practice activities (PKD 8622Z);
- physiotherapy activities (PKD 8690A);
- dental practice activities (PKD 8623Z);
- other health care activities not elsewhere classified (PKD 8690Z).

2. DURATION OF THE COMPANY

The Company was established for indefinite period.

3. PERIODS COVERED BY THE QUARTERLY CONDENSED FINANCIAL STATEMENTS

Period covered by the guarterly condensed financial statements presented:

from 1 January to 30 September 2013.

Periods for which comparative financial data are presented:

- from 1 January to 31 December 2012;
- from 1 January to 30 September 2012.

4. COMPOSITION OF THE MANAGEMENT AND SUPERVISORY AUTHORITIES

Management Board of the Company:

- Adam Stanisław Rozwadowski President of the Management Board;
- Jacek Jakub Rozwadowski Vice President of the Management Board.

(All amounts are stated in PLN'000 unless otherwise indicated)

Supervisory Board of the Company:

- Anna Maria Rozwadowska;
- Janusz Ryszard Jakubowski;
- Anna Piszcz;
- Zbigniew Okoński;
- Adam Ciuhak

5. INFORMATION WHETHER QUARTERLY CONDENSED FINANCIAL STATEMENTS AND COMPARATIVE DATA INCLUDE CONSOLIDATED DATA

Neither condensed financial statements nor comparative financial data include consolidated data. The Company does not have any units drawing up individual condensed quarterly financial statements.

6. INFORMATION WHETHER THE ISSUER IS A PARENT COMPANY, SHAREHOLDER IN A CO-SUBSIDIARY OR A SIGNIFICANT INVESTOR, AND WHETHER IT DRAWS UP THE CONDENSED QUARTERLY CONSOLIDATED FINANCIAL STATEMENTS

The Company is a parent company for Enelbud Sp. z o.o. and Centrum Medyczne Diagnostyka Sp. z o.o. The Company does not draw up the quarterly condensed consolidated financial statements, based on the exemption provided for in Article 58 of the Polish Accounting Act. The Company is not a shareholder in a co-subsidiary or a significant investor in other entities.

7. INFORMATION ON BUSINESS COMBINATIONS DURING THE PERIOD COVERED BY THE CONDENSED QUARTERLY FINANCIAL STATEMENTS AND COMPARATIVE DATA

Neither condensed quarterly financial statements nor comparative financial data include the results of the settlement of any business combinations.

8. GOING CONCERN ASSUMPTION

The condensed quarterly financial statements have been prepared assuming that the Company will continue as a going concern in the foreseeable future, and that it will not and does not have to discontinue activities or significantly limit their scope. The Management Board of the Company does not have any knowledge of circumstances indicating a threat to the going concern basis.

9. INFORMATION ON CHANGES IN ACCOUNTING PRINCIPLES (POLICY) APPLIED

Accounting principles did not change during the period covered by the financial statements. These principles were applied continuously during all periods presented.

Accounting principles applied in the preparation of the condensed quarterly financial statements comply with the Accounting Act of 29 September 1994 as amended (hereinafter referred to as the Accounting Act).

(All amounts are stated in PLN'000 unless otherwise indicated)

CONDENSED QUARTERLY FINANCIAL STATEMENTS OF Centrum Medyczne ENEL-MED S.A. BALANCE SHEET

ASSETS	30.09.2013	30.06.2013	31.12.2012	30.09.2012
I. Non-current assets	94,862	98,427	104,127	105,960
1. Intangible assets, of which:	1,620	1,660	1,858	1,939
- goodwill				
2. Tangible fixed assets	85,245	88,440	94,610	96,831
3. Long-term receivables	580	740	581	617
3.1. From related entities				
3.2. From other entities	580	740	581	617
4. Long-term investments	4,878	4,840	4,741	4,674
4.1. Real estates				
4.2. Intangible assets				
4.3. Long-term financial assets	4,878	4,840	4,741	4,674
a) in related entities, of which:	645	640	640	640
- shares in controlled entities, measured using the equity method	645	640	640	640
b) in other entities	4,233	4,200	4,101	4,034
4.4. Other long-term investments				
5. Long-term prepayments	2,538	2,748	2,337	1,900
5.1. Deferred tax assets	2,538	2,748	2,337	1,900
5.2. Other prepayments				
II. Current assets	16,195	16,408	14,653	16,195
1. Inventories	913	932	1,005	1,104
2. Short-term receivables	12,205	12,948	11,139	10,272
2.1. From related entities	1	1	1	3
2.2. From other entities	12,204	12,946	11,138	10,269
3. Short-term investments	1,158	612	409	695
3.1. Short-term financial assets	1,158	612	409	695
a) in related entities				
b) in other entities		_	_	
c) cash, cash equivalents, and other monetary assets	1,158	612	409	695
3.2. Other short-term investments				
4. Short-term prepayments	1,919	1,917	2,100	4,125
Total assets	111,057	114,836	118,780	122,155

(All amounts are stated in PLN'000 unless otherwise indicated)

BALANCE SHEET

EQUITY AND LIABILITIES	30.09.2013	30.06.2012	31.12.2012	30.09.2012
I. Equity	44,071	42,767	44,161	47,164
1. Share capital:	23,567	23,567	23,567	23,567
2. Call-up share capital not paid (negative amount)				
3. Treasury shares (negative amount)				
4. Supplementary capital	29,992	29,991	29,991	29,992
5. Revaluation reserve				
6. Other reserve capitals				
7. Retained earnings (accumulated losses)	-9,398	-9,398	-566	-567
8. Net profit (loss)	-90	-1,394	-8,831	-5,827
9. Appropriations of net profit during the financial year				
II. Liabilities and provisions for liabilities	66,986	72,069	74,619	74,991
1. Provisions for liabilities	2,563	2,425	2,162	1,912
1.1. Provision for deferred income tax	1,923	1,785	1,488	1,279
1.2. Provision for pension and similar benefits	640	640	640	633
a) long-term	170	170	170	130
b) short-term	470	470	470	503
1.3. Other provisions			34	
a) long-term				
b) short-term			34	
2. Long-term liabilities	24,964	27,715	32,436	33,560
2.1. To related entities				
2.2. To other entities	24,964	27,715	32,436	33,560
3. Short-term liabilities	39,162	41,571	39,738	39,218
3.1. To related entities	175	175	635	358
3.2. To other entities	38,915	41,324	39,087	38,804
3.3. Special funds	72	72	16	55
4. Accruals	297	359	283	302
4.1. Negative goodwill				
4.2. Other accruals	297	359	283	302
a) long-term	121	100	12	136
b) short-term	176	259	271	166
Total equity and liabilities	111,057	114,836	118,780	122,155

Book value (PLN'000)	44,071	42,767	44,161	47,164
Number of shares	23,566,900	23,566,900	23,566,900	23,566,900
Book value per share (PLN)	1.87	1.81	1.87	2.00
Diluted number of shares	23,566,900	23,566,900	23,566,900	23,566,900
Diluted book value per share (PLN)	1.87	1.81	1.87	2.00

(All amounts are stated in PLN'000 unless otherwise indicated)

PROFIT AND LOSS ACCOUNT

PROFIT AND LOSS ACCOUNT	01.01.2013 – 30.09.2013	01.01.2012 – 30.09.2012	01.07.2013 – 30.09.2013	01.07.2012 – 30.09.2012
I. Net revenues from sales of products, goods and materials, of which:	147,451	134,526	49,776	45,664
- to related entities				
Net revenues from sales of products	147,451	134,526	49,776	45,664
2. Net revenues from sales of goods and materials				
II. Cost of products, goods and materials sold, of which:	136,886	129,843	44,658	43,098
- to related entities				
Manufacturing cost of the products sold	136,886	129,843	44,658	43,098
2. Value of goods and materials sold				
III. Goss profit (loss) from sales (I-II)	10,565	4,683	5,118	2,566
IV. Selling costs	5,185	5,099	1,657	1,525
V. General and administrative costs	4,426	4,718	1,397	1,290
VI. Profit (loss) on sales (III-IV-V)	954	-5,133	2,064	-249
VII. Other operating income	1,404	561	258	202
Gain on disposal of non-financial, non-current assets	101	85	-57	73
2. Subsidies	181	157	78	55
3. Other operating income	1,122	320	237	74
VIII. Other operating costs	293	383	42	53
1. Loss on disposal of non-financial, non-current assets				
2. Revaluation of non-financial assets		100		14
3. Other operating costs	293	283	42	38
IX. Operating profit (loss) (VI+VII-VIII)	2,066	-4,955	2,281	-100
X. Financial income	135	222	34	72
1. Dividends and share in profits, of which:				
- from related entities				
2. Interest, of which:	135	222	34	72
- from related entities				
3. Gain on disposal of investments				
4. Revaluation of investments				
5. Other				
XI. Financial costs	2,006	2,008	612	813
1. Interest, of which:	1,969	1,941	597	794
- to related entities				
2. Loss on disposal of investments				
3. Revaluation of investments				
4. Other	37	67	16	20
XII. Profit (loss) on business activities (IX+X-XI)	195	-6,740	1,703	-842
XIII. Net extraordinary gains/losses (XIII.1. – XIII.2.)				
1. Extraordinary gains				
2. Extraordinary losses				
XIV. Profit (loss) before tax (XII+/-XIII)	195	-6,740	1,703	-842
XV. Income tax	284	-913	398	-75
a) current part	51	16		
b) deferred part	233	-929	348	-75
XVI. Other statutory profit reductions (loss increases)				
XVII. Share in net profit (loss) of controlled entities recognised under the equity method				
XVIII. Net profit (loss) (XIV-XV-XVI+/-XVI)	-90	-5,827	1,304	-767

(All amounts are stated in PLN'000 unless otherwise indicated)

STATEMENT OF CHANGES IN EQUITY

	30.09.2013	31.12.2012	30.09.2012
I. Opening balance of equity	44,161	53,699	53,699
a) changes in adopted accounting principles (policy)			
b) adjustment of errors			
I.a. Opening balance of equity after reconciliation to comparative data	44,161	53,699	53,699
1. Opening balance of share capital	23,567	23,567	23,567
1.1. Changes in share capital			
a) increases (due to)			
- issue of shares			
b) decreases			
1.2. Closing balance of share capital	23,567	23,567	23,567
2. Opening balance of called-up share capital not paid			
2.1. Changes in called-up share capital not paid			
a) increases			
b) decreases			
2.2. Closing balance of called-up share capital not paid			
3. Opening balance of treasury shares			
3.1. Changes in treasury shares			
a) increases			
b) decreases			
3.2. Closing balance of treasury shares			
4. Opening balance of supplementary capital	29,991	26,611	26,611
4.1. Changes in supplementary capital		3,380	3,380
a) increases (due to)		3,380	3,380
- issue of shares with a premium over the nominal value			
- profit distribution (statutory)		3,380	3,380
b) decreases (due to)			
- costs related to introduction to listing on the stock exchange			
4.2. Closing balance of supplementary capital	29,991	29,991	29,991
5. Opening balance of revaluation reserve			
5.1. Changes in revaluation reserve			
a) increases (due to)			
b) decreases (due to)			
5.2. Closing balance of the revaluation reserve			
6. Opening balance of other reserve capitals			
6.1. Changes in other reserve capitals			
a) increases (due to)			
b) decreases (due to)			
6.2. Closing balance of other reserve capitals			
7. Opening balance of retained earnings / (accumulated losses)	-9,398	3,521	3,521
7.1. Opening balance of retained earnings		4,087	4,087
a) changes in adopted accounting principles (policy)			
b) adjustment of errors			
7.2. Opening balance of retained earnings after reconciliation to comparative data			
a) increases (due to)		4,087	4,087
- allocation of the profit for previous years		4,087	4,087

(All amounts are stated in PLN'000 unless otherwise indicated)

	30.09.2013	31.12.2012	30.09.2012
b) decreases (due to)		4,087	4,087
- reclassification to supplementary capital		3,380	3,380
- dividend payments		707	707
7.3. Closing balance of retained earnings		0	0
7.4. Opening balance of accumulated losses	-9,398	-566	-566
a) changes in adopted accounting principles (policy)			
b) adjustment of errors			
7.5. Opening balance of accumulated losses after reconciliation to comparative data	-9,398	-566	-566
a) increases (due to)			
- reclassification of accumulated losses to be covered			
b) decreases (due to)			
7.6. Closing balance of accumulated losses	-9,398	-566	-566
7.7. Closing balance of retained earnings / (accumulated losses)	-9,398	-566	-566
8. Net result	-90	-8,831	-5,827
a) net profit			
b) net loss	-90	-8,831	-5,827
c) correction of errors (loss)			
II. Closing balance of equity	44,071	44,161	47,164
III. Equity as adjusted for the proposed profit distribution (offset of loss)	44,071	44,161	47,164

(All amounts are stated in PLN'000 unless otherwise indicated)

CASH FLOW STATEMENT – INDIRECT METHOD

	01.01.2013 - 30.09.2013	01.01.2012 - 30.09.2012	01.07.2013 - 30.09.2013	01.07.2012 - 30.09.2012
A. Cash flows from operating activities				
I. Net profit (loss)	-90	-5,827	1,304	-767
II. Total adjustments	11,309	11,823	5,066	2,390
1. Depreciation and amortisation	10,846	10,690	3,409	3,856
2. Exchange (gains) losses				
3. Interest and share in profits (dividends)	1,750	1,764	513	786
4. (Gain) (loss) on investing activities	-101	-85	57	-85
5. Change in provisions	401	527	138	-155
6. Change in inventories	92	-142	19	-100
7. Change in receivables	-914	764	883	220
8. Change in short-term liabilities, excluding loans and borrowings	-623	127	-62	-764
9. Change in accruals, prepayments and deferred income	-8	-1,648	146	-1,350
10. Other adjustments	-135	-174	-36	-18
III. Net cash flows from operating activities (I+/-II)	11,219	5,995	6,371	1,623
B. Cash flows from investing activities				
I. Inflows	188	2,414	188	2,342
Disposal of intangible assets and tangible fixed assets	188	2,414	188	2,342
2. Disposal of investments in real estate and intangible assets				
3. From financial assets, of which:				
a) in related entities				
- disposal of financial assets				
- dividends and share in profits				
- repayment of long-term loans granted				
- interest				
- other inflows from financial assets				
b) in other entities				
- disposal of financial assets				
- dividends and share in profits				
- repayment of long-term loans granted				
- interest				
- other inflows from financial assets				
4 . Other inflows from investing activities				
II. Outflows	2,058	16,312	462	3,155
Purchase of intangible assets and tangible fixed assets	2,058	16,312	462	3,155
2. Investments in real estate and intangible assets				
3. On financial assets, of which:				
a) in related entities				
- purchase of financial assets				
- long-term loans granted				
b) in other entities				
- purchase of financial assets				
- long-term loans granted				
4. Other outflows on investing activities				
III. Net cash flows from investing activities (I - II)	-1,870	-13,899	-274	-814
C. Cash flows from financial activities				
I. Inflows	14,265	18,817	-2,102	2,352

QUARTERLY CONDENSED FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. FOR THE PERIOD FROM 01 JANUARY TO 30 SEPTEMBER 2013 (All amounts are stated in PLN'000 unless otherwise indicated)

	01.01.2013 - 30.09.2013	01.01.2012 – 30.09.2012	01.07.2013 - 30.09.2013	01.07.2012 – 30.09.2012
Net inflows from issue of shares and other equity instruments and capital contributions				
2. Loans and borrowings	14,096	18,664	-2,170	2,298
3. Issue of debt securities				
4. Other financial inflows	169	153	68	54
II. Outflows	22,865	14,745	3,448	3,049
Purchase of treasury shares				
2. Dividends and other payments to shareholders				
Outflows due to profit distribution other than payments to shareholders				
4. Repayment of loans and borrowings	19,009	11,841	2,366	1,845
5. Redemption of debt securities				
6. Due to other financial liabilities				
7. Repayment of financial lease liabilities	1,543	1,079	479	395
8. Interest	2,312	1,825	604	810
9. Other outflows on financial activities				
III. Net cash flows from financial activities (I - II)	-8,601	4,072	-5,550	-698
D. Total net cash flows (A.III.+B.III+/-C.III)	749	-3,831	546	112
E. Change in cash and cash equivalents in the balance sheet, including:	749	-3,831	546	112
- change in cash and cash equivalents due to changes in exchange rates				
F. Cash opening balance	409	4,526	612	582
G. Cash closing balance (F+/-D), of which:	1,158	695	1,158	695
- restricted cash and cash equivalents				

(All amounts are stated in PLN'000 unless otherwise indicated)

ADDITIONAL NOTES TO THE CONDENSED QUARTERLY FINANCIAL STATEMENTS

1. SIGNIFICANT CHANGES IN ESTIMATES

A. INFORMATION ON SIGNIFICANT CHANGES IN PROVISIONS FOR PENSION AND SIMILAR BENEFITS

CHANGES IN LONG-TERM PROVISION FOR PENSION AND SIMILAR BENEFITS	provision for retirement benefits
a) as at 01 January 2013	170
b) increases	
c) used	
d) released	
e) as at 30 September 2013	170

CHANGES IN SHORT-TERM PROVISION FOR PENSION AND SIMILAR BENEFITS	provision for retirement benefits	provision for unused holidays
a) as at 01 January 2013	9	461
b) increases		
c) used		
d) released		
e) as at 30 September 2013	9	461

B. INFORMATION ON SIGNIFICANT CHANGES IN OTHER PROVISIONS CHANGES IN OTHER LONG-TERM PROVISIONS – not applicable.

CHANGES IN OTHER SHORT-TERM PROVISIONS	provision for audit/review of the financial statements
a) as at 01 January 2013	34
b) increases (due to)	
c) used (due to)	34
d) released (due to)	
e) as at 30 September 2013	

(All amounts are stated in PLN'000 unless otherwise indicated)

C. INFORMATION ON SIGNIFICANT CHANGES IN THE PROVISION FOR DEFERRED TAX AND THE DEFERRED TAX ASSET

CHANGE IN DEFERRED TAX ASSET	01.01.2013-30.09.2013
1. Opening balance of the deferred tax assets, of which:	2,337
a) charged to the financial result	2,337
unpaid payroll and social insurance premiums	291
provision for unused holidays	88
provision for retirement benefits	34
unpaid accrued interest	14
impairment write-down on receivables	181
other provisions	118
profit difference on sale and leaseback transaction	38
tax loss for 2012	1,566
provision for the audit of the financial statements	7
b) charged to equity	
c) charged to goodwill or negative goodwill	
2. Increases	323
a) charged to the financial result for the period in relation to negative temporary differences (due to)	323
unpaid payroll and social insurance premiums	23
unpaid accrued interest	2
tax loss for 2013	298
b) charged to the financial result for the period in relation to tax loss (due to)	
c) charged to equity in relation to negative temporary differences	
d) charged to equity in relation to tax loss	
e) charged to goodwill or negative goodwill in relation to negative temporary differences	
3. Decreases	122
a) charged to the financial result for the period in relation to negative temporary differences (due to)	122
provision for the audit of the financial statements	7
impairment write-down on receivables	26
profit difference on sale and leaseback transaction	10
other provisions	79
b) charged to the financial result for the period in relation to tax loss	
c) charged to equity in relation to negative temporary differences	
d) charged to equity in relation to tax loss	
e) charged to goodwill or negative goodwill in relation to negative temporary differences	
4. Closing balance of the deferred tax assets, total, of which:	2,538
a) charged to the financial result	2,538
unpaid payroll and social insurance premiums	314
impairment write-down on receivables	155
unpaid accrued interest	17
other provisions	38
provision for unused holidays	88
tax loss for 2012	1,566
tax loss for 2013	299
profit difference on sale and leaseback transaction	27
provision for retirement benefits	34

QUARTERLY CONDENSED FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. FOR THE PERIOD FROM 01 JANUARY TO 30 SEPTEMBER 2013 (All amounts are stated in PLN'000 unless otherwise indicated)

b) charged to equity	
c) charged to goodwill or negative goodwill	

TEMPORARY NEGATIVE DIFFERENCES (basis)	Expiry date	30.09.2013
I ASSETS		818
impairment write-down on receivables	next financial year	818
II EQUITY AND LIABILITIES		12,540
unpaid payroll and social insurance premiums	next 2 months	1,652
unpaid accrued interest	next financial year	88
other provisions	next financial year	201
provision for unused holidays	next financial year	461
profit difference on sale and leaseback transaction	31.12.2017	146
tax loss for 2012	31.12.2017	8,242
tax loss for 2013	31.12.2018	1,571
provision for retirement benefits	next financial year	179
Total		13,358

CHANGES IN THE DEFERRED TAX PROVISION	01.01 - 30.09.2013
1. Opening balance of the deferred tax provision, of which:	1,488
a) charged to the financial result	1,488
unpaid accrued interest on loans	142
fixed assets leased	62
difference of the carrying amount and tax value of fixed assets	1,252
revenues to be settled for tax purposes in the next year	32
b) charged to equity	
c) charged to goodwill or negative goodwill	
2. Increases	467
a) charged to the financial result for the period due to positive temporary differences (due to)	467
unpaid accrued interest on loans	25
difference of the carrying amount and tax value of fixed assets	422
fixed assets leased	20
b) charged to equity in relation to positive temporary differences (due to)	
c) charged to goodwill or negative goodwill in relation to positive temporary differences	
3. Decreases	32
a) charged to the financial result for the period in relation to positive temporary differences (due to)	32
revenues to be settled for tax purposes in the next year	32
b) charged to equity in relation to positive temporary differences	
c) charged to goodwill or negative goodwill in relation to positive temporary differences	

(All amounts are stated in PLN'000 unless otherwise indicated)

4. Closing balance of the provision for deferred tax, total	1,923
a) charged to the financial result	1,923
unpaid accrued interest on loans	167
fixed assets leased	82
difference of the carrying amount and tax value of fixed assets	1,674
b) charged to equity	
c) charged to goodwill or negative goodwill	

Positive temporary differences	Expiry date	30.09.2013	
I ASSETS		10,120	
unpaid accrued interest on loans	31.12.2015	880	
fixed assets leased	31.12.2015	432	
difference of the carrying amount and tax value of fixed assets	31.12.2020	8,808	
II EQUITY AND LIABILITIES			
Total		10,120	

D. INFORMATION ON SIGNIFICANT CHANGES IN IMPAIRMENT WRITE-DOWNS ON ASSETS

• CHANGES IN INTANGIBLE ASSETS AND RELATED IMPAIRMENT WRITE-DOWNS

INTANGIBLE ASSETS	30.09.2013	31.12.2012	30.09.2012
a) costs of completed development projects			
b) goodwill			
c) concessions, patents, licences and similar assets purchased, of which:			
- computer software			
d) other intangible assets	1,620	1,858	1,939
e) prepayments for intangible assets			
Total intangible assets	1,620	1,858	1,939

(All amounts are stated in PLN'000 unless otherwise indicated)

CHANGES IN INTANGIBLE ASSETS	costs of		licence	sions, patents, es and similar purchased, of which			
(by group)	completed developmen			computer	other intangible	prepayments for intangible	Total intangible
30.09.2013	t projects	goodwill		software	assets	assets	assets
a) opening balance of gross value of intangible assets		131			4,429		4,560
b) increases (due to)					148		148
purchase					35		35
settlement of constructions in progress					113		113
c) decreases					26		26
- liquidation					26		26
d) closing balance of gross value of intangible assets		131			4,552		4,683
e) opening balance of accumulated amortisation		131			2,571		2,702
f) amortisation for the period (due to)					360		360
- wear and tear					386		386
- liquidation					-26		-26
g) closing balance of accumulated amortisation		131			2,932		3,063
h) opening balance of impairment write-downs							
- increases							
- decreases							
i) closing balance of write- downs due to permanent impairment							
j) closing balance of net value of intangible assets		0			1,620		1,620

• CHANGES IN TANGIBLE FIXED ASSETS AND RELATED IMPAIRMENT WRITE-DOWNS

TANGIBLE FIXED ASSETS	30.09.2013	31.12.2012	30.09.2012
a) fixed assets, of which:	84,334	93,485	95,852
- land (including rights to perpetual usufruct)	519	519	519
- buildings, offices and apartments, civil and marine engineering facilities	5,686	5,895	5,968
- technical equipment and machines	3,742	4,339	4,695
- vehicles	375	351	387
- other tangible fixed assets	74,012	82,381	84,282
b) constructions in progress	911	1,125	979
c) prepayments for constructions in progress			
Tangible fixed assets, total	85,245	94,610	96,831

(All amounts are stated in PLN'000 unless otherwise indicated)

CHANGES IN TANGIBLE FIXED ASSETS (by group) 30.09.2013	land (including rights to perpetual usufruct)	buildings, offices and apartments, civil and marine engineering facilities	technical equipment and machines	vehicles	other tangible fixed assets	Total tangible fixed assets
a) opening balance of gross value of tangible fixed assets	519	7,559	8,229	959	124,927	142,193
b) increases (due to)		9	371	102	1,066	1,548
purchase		9	225	102	474	819
settlement of constructions in progress			146		592	738
c) decreases (due to)			216		3,653	3,869
liquidation					3,126	3,126
sale			216		527	743
d) closing balance of gross value of tangible fixed assets	519	7,568	8,384	1,061	122,340	139,872
e) opening balance of accumulated depreciation		1,644	3,890	608	42,546	48,708
f) depreciation for the period (due to)		218	752	77	5,782	6,830
wear and tear		218	968	77	9,197	10,460
liquidation					-2,935	-2,935
sale			-216		-479	-696
g) closing balance of accumulated depreciation		1,882	4,642	685	48,328	55,537
h) opening balance of impairment write- downs						
- increases						
- decreases						
i) closing balance of write-downs due to permanent impairment						
j) closing balance of net value of tangible fixed assets	519	5,686	3,742	375	74,012	84,334

• CHANGES IN INVENTORIES AND RELATED IMPAIRMENT WRITE-DOWNS

DESCRIPTION	30.09.2013	31.12.2012	30.09.2012
Materials (gross)	913	1,005	1,004
Materials (write-downs)			
Materials (net)	913	1,005	1,004
Semi-finished products and work in progress (net)			
Finished products (net)			
Good (net)			

No impairment changes in write-downs on inventories were recognised during the period covered by the financial statements.

(All amounts are stated in PLN'000 unless otherwise indicated)

• INFORMATION ON IMPAIRMENT WRITE-DOWNS ON FINANCIAL ASSETS

No changes in impairment write-downs on financial assets were recognised during the period covered by the financial statements.

CHANGES IN LONG-TERM RECEIVABLES AND RELATED IMPAIRMENT WRITE-DOWNS

LONG-TERM RECEIVABLES	30.09.2013	31.12.2012	30.09.2012
a) from related entities			
b) from other entities (due to)	580	582	617
- deposit	580	582	617
Long-term receivables, net	580	582	617
a) impairment write-downs on receivables			
Long-term receivables, gross	580	582	617

No changes in impairment write-downs on long-term receivables were recognised during the period covered by the financial statements.

• CHANGES IN SHORT-TERM RECEIVABLES AND RELATED IMPAIRMENT WRITE-DOWNS

SHORT-TERM RECEIVABLES	30.09.2013	31.12.2012	30.09.2012
a) from related entities	1	1	3
- trade receivables, due:	1	1	3
- up to 12 months	1	1	3
- above 12 months			
- claimed in court			
- other			
b) receivables from other entities	12,204	11,138	10,269
- trade receivables, due:	12,150	10,957	10,198
- up to 12 months	12,150	10,957	10,198
- above 12 months			
- tax, subsidy, customs duty, social insurance and health insurance and other benefits receivable		24	
- claimed in court			
- other	54	157	71
Total short-term receivables, net	12,205	11,139	10,272
c) impairment write-downs on receivables	818	954	906
Total short-term receivables, gross	13,023	12,093	11,178

QUARTERLY CONDENSED FINANCIAL STATEMENTS OF CENTRUM MEDYCZNE ENEL-MED S.A. FOR THE PERIOD FROM 01 JANUARY TO 30 SEPTEMBER 2013 (All amounts are stated in PLN'000 unless otherwise indicated)

TRADE RECEIVES (GROSS) – WITH MATURITY REMAINING AFTER THE BALANCE SHEET DATE	30.09.2013
a) up to 1 month	8,609
b) over 1 month and up to 3 months	
c) over 3 months and up to 6 months	
d) over 6 months and up to 1 year	
e) over 1 year	
f) overdue receivables	4,360
Total trade receivables (gross)	12,969
g) impairment write-downs on trade receivables:	818
Trade receivables, total (net)	12,151

OVERDUE TRADE RECEIVABLES (GROSS) – BY PERIOD OUTSTANDING	30.09.2013
a) up to 1 month	2,919
b) over 1 month and up to 3 months	410
c) over 3 months and up to 6 months	100
d) over 6 months and up to 1 year	64
e) over 1 year	867
Total overdue trade receivables (gross)	4,360
f) impairment write-downs on overdue trade receivables	818
Total overdue trade receivables (net)	3,542

SHORT-TERM RECEIVABLES FROM RELATED PARTIES	30.09.2013
a) trade receivables, of which:	1
- from subsidiaries	1
- from co-subsidiaries	
- from associated entities	
- from a significant investor	
- from a shareholder of a co-subsidiary	
- from a parent company	
b) other	
c) claimed in court	
Total short-term receivables from related parties, net	1
d) impairment write-downs on receivables from related parties	
Total short-term receivables from related parties, gross	1

CHANGE IN IMPAIRMENT WRITE-DOWNS ON SHORT-TERM RECEIVABLES	30.09.2013
Opening balance	954
a) increases (due to)	
b) decreases (due to)	136
Closing balance of impairment write-downs on short-term receivables	818

(All amounts are stated in PLN'000 unless otherwise indicated)

2. DESCRIPTION OF MATERIAL ACHIEVEMENTS AND FAILURES OF THE ISSUER DURING THE PERIOD COVERED BY THE QUARTERLY CONDENSED FINANCIAL STATEMENTS, ALONG WITH INFORMATION ON RELATED KEY EVENTS

After the period of intensive investments at the end of 2011 and beginning of 2012, in 2013 the Company focused on activities aimed at increasing sales of its services, especially commercial sales in all business lines.

Taking into consideration sales in all business lines, in the first three quarters of 2013, the Company recorded a growth of revenues by 10% vs. the same period in the previous year. Compared with the third quarter of 2012, in the third quarter 2013, the Company achieved 18% sales growth in the area of diagnostic imaging and 11% in the area of pre-paid medical plans. The Company is gradually increasing sales of commercial services in hospitals. During three quarters in 2013, the value of commercial operations at hospitals increased by 41% vs. the same period in the previous year.

During the reporting period, the Company acquired new corporate clients, including inter alia, LG Electronics Wrocław, another company from the LG Cluster. The agreement with the new client was concluded for two years, and its value depends on the number of persons covered by the package in a given month, and might reach about PLN 1,440,000 during the term of the agreement. It is worthy to note that at the end of December 2012 and beginning of January 2013, the Company concluded with companies from the LG Cluster agreements for PLN 4,270,000. Additionally, ENEL-MED established the cooperation with Ruch (value of the agreement for five years is minimum PLN 1,500,000) and extended the agreement with three companies from the PGE group - agreements were concluded for three years, and in the case of services in the field occupational medicine provided to PGE Obrót S.A. - for two years. The total value of agreements may reach about PLN 4.544.028.00, Additionally, the Company extended the cooperation with UNIQA Towarzystwo Ubezpieczeń by adding insurance for employees, partners and their families. It is worthy to note that the cooperation with the insurance firm until now covered only the provision of medical services to customers of the company, who acquired medical insurance policies, while in this case, the client decided to offer medical packages to their employees. The agreement was concluded for indefinite period and its value during five years may reach about PLN 3,200,000.

The third quarter of 2013 resulted in signing other agreements, including, *inter alia*, with the National Bank of Poland or Raiffeisen Bank Polska. The agreement with the National Bank of Poland, increasing the previous value of pre-paid medical plans while extending the scope of services, was concluded for 24 months with an option to extend it by the National Bank of Poland for additional 12 months. The value of this agreement depends on the number of persons covered by pre-paid medical plans, and might reach about PLN 7,588,992.00 gross for 24 months. At the same time, the annex to the agreement with Raiffeisen Bank Polska has added about 3,000 employees of Polbank (the company acquired by Raiffeisen Bank Polska) and their families to the group of persons covered by pre-paid medical plans. The annex to the agreement was concluded for 17 months without an early termination option, with an option to automatically extend it for the next 19 months, and its value depends on the number of persons covered by pre-paid medical plans, and might reach about PLN 6,455,462.00 for 17 months.

Additionally, the Company signed the annex to the space lease agreement for the purposes of the multi-profile outpatient clinic in Poznań. The annex has reduced lease costs by PLN 500,000.00 in 2013.

During the reporting period, the Company also signed agreements for the provision of hospital treatment services and imaging diagnostic services with the National Health Fund. The Company concluded an annex to the agreement for the provision of health care services in form of hospital treatment in the field of neurosurgery, orthopaedics, general surgery, otolaryngology, ophthalmology and vascular surgery. Medical services are provided in two hospitals of Centrum Medyczne ENEL-MED located in Warsaw: Centrum Hospital (neurosurgery and orthopaedics) and Zacisze Hospital (other areas). The value of the agreement with the National Health Fund for 2013 is PLN 5,130,580. The agreement with the National Health Fund for the provision of diagnostic services in the field of computed tomography, gastroscopy and colonoscopy, in the Masovian Voivodeship, is also a significant agreement. Services are provided in Warsaw (Bielany Diagnostic Centre and Zacisze diagnostic laboratory) and at the diagnostic laboratory in Wołomin. Total value of services for 2013 is PLN 5,170,149. Additionally, the Company concluded with the National Health Fund the agreement for

(All amounts are stated in PLN'000 unless otherwise indicated)

magnetic resonance imaging services at the diagnostic laboratory in Gdańsk, the most recent diagnostic laboratory of the Company. The maximum value of the agreement for the second half of 2013 is PLN 822,787.20.

During the period covered by the quarterly condensed financial statements the Company established wider cooperation with its long-term client – Bank Millennium S.A. by concluding two agreements: the agreement for a multi-product line and the agreement for a mortgage credit for companies. The agreement for the mortgage credit for companies in the amount of PLN 5,222,000 was signed for the period from 25 March 2013 to 24 May 2017. In accordance with the second agreement with the Bank for a multi-product line, the Bank granted the Company a global limit of PLN 20,000,000 for the period from 25 March 2013 to 24 March 2014. As a result of concluding the agreement with Bank Millennium, the Company terminated the agreement for the multi-product line for PLN 15,000,000 with Credit Agricole Bank Polska S.A. In the fourth quarter 2013, the annex to the agreement was concluded, of which the Company notified in point 16 in the additional information to the quarterly condensed financial statements.

Additionally, in relation to the opening of a new multi-profile outpatient clinic in Warsaw in the Atrium Promenada Shopping Centre, planned for the first half of 2014, Enelbud Sp. z o.o., a subsidiary of Centrum Medyczne ENEL-MED S.A. concluded with POL-K ATALLIAN the agreement based on which Enelbud will carry out, based on the order of POL-K ATALLIAN, works involving refurbishment of the space for the purposes of the ENEL-MED outpatient clinic. The contractual lump-sum fee for the proper performance of the subject matter of the agreement, including elimination of faults, is PLN 6,912,780.67 net.

3. DESCRIPTION OF FACTORS AND EVENTS, ESPECIALLY OF NON-RECURRING NATURE, WITH A MATERIAL BEARING ON THE FINANCIAL RESULT ACHIEVED

The Company is still focusing its activities on sales of services offered and on ensuring the potential at existing facilities. The potential of recently established branches that started functioning in 2012 – the multi-profile outpatient clinic with a diagnostic laboratory in Gdańsk as well as the Centrum Hospital and Diagnostic Centre in Warsaw is gradually being better utilised. In the third quarter 2013, savings resulting from negotiations of contracts with suppliers were materialising in a greater extent. Better utilisation of the Company's potential translated into a significant improvement of the financial result and this trend will continue in forthcoming quarters.

4. INFORMATION ON SEASONAL AND CYCLICAL CHANGES IN ACTIVITIES OF THE ISSUER IN THE REPORTING PERIOD

Sales of pre-paid medical plans to corporate clients are one of the pillars of the Issuer's activities. The third quarter, which is a holiday season, was the period of decreased incidence of diseases, and thus the Company recorded a lower number of patients covered by pre-paid medical plans using medical services, which has a positive impact on the Company's financial result.

5. INFORMATION ON SIGNIFICANT TRANSACTIONS INVOLVING THE ACQUISITION AND SALE OF TANGIBLE FIXED ASSETS

No significant transactions involving sale of tangible fixed assets took place during the reporting period.

6. INFORMATION ON SIGNIFICANT LIABILITIES ARISING FROM THE PURCHASE OF TANGIBLE FIXED ASSETS

No significant liabilities arising from the purchase of tangible fixed assets occurred in the third quarter of 2013.

7. INFORMATION ON SIGNIFICANT SETTLEMENTS RELATING TO COURT CASES

In the third quarter of 2013, there were no significant settlements relating to court cases.

(All amounts are stated in PLN'000 unless otherwise indicated)

8. CORRECTIONS OF ERRORS WITH RESPECT TO PREVIOUS PERIODS

Not applicable.

9. INFORMATION ON CHANGES OF THE ECONOMIC SITUATION AND BUSINESS CONDITIONS MATERIALLY AFFECTING THE FAIR VALUE OF THE ISSUER'S FINANCIAL ASSETS AND FINANCIAL LIABILITIES

In the third quarter of 2013, there were no changes of the economic situation and business conditions materially affecting the fair value of the Company's financial assets and financial liabilities.

10. INFORMATION ON FAILURE TO REPAY A CREDIT FACILITY OR LOAN AND/OR ON BREACH OF MATERIAL PROVISIONS OF A CREDIT OR LOAN AGREEMENT WITH RESPECT TO WHICH NO CORRECTIVE ACTIONS WERE TAKEN BY THE END OF THE REPORTING PERIOD

Not applicable.

11. INFORMATION ON RELATED-PARTY TRANSACTIONS CONCLUDED BY THE ISSUER OR ITS SUBSIDIARY ON TERMS OTHER THAN AN ARM'S LENGTH BASIS

No related-party transactions on terms other than an arm's length basis were concluded in the reporting period by the Company or its subsidiary.

12. INFORMATION ON CHANGES OF THE METHOD FOR FAIR VALUE DETERMINATION

In the third quarter of 2013, no changes of the method for fair value determination occurred.

13. INFORMATION ON CHANGES TO THE CLASSIFICATION OF FINANCIAL ASSETS AS A RESULT OF CHANGES OF THE PURPOSE OR USE OF SUCH ASSETS

In the third quarter of 2013, no changes to the classification of financial assets as a result of changes of the purpose or use of such assets occurred.

14. INFORMATION ON ISSUANCE, REDEMPTION AND REPAYMENT OF NON-EQUITY AND EQUITY SECURITIES

Not applicable.

15. INFORMATION ON DIVIDEND PAID OUT (OR DECLARED), INCLUDING AGGREGATE AND PER SHARE VALUE, SEPARATELY FOR ORDINARY AND PREFERENCE SHARES

The Company did not pay or declare any dividend payments.

(All amounts are stated in PLN'000 unless otherwise indicated)

16. EVENTS SUBSEQUENT TO THE DATE OF THE QUARTERLY CONDENSED FINANCIAL STATEMENTS, WHICH HAVE NOT BEEN ACCOUNTED FOR IN THESE STATEMENTS BUT MAY HAVE A MATERIAL BEARING ON FUTURE FINANCIAL RESULTS OF THE ISSUER

In October 2013, Centrum Medyczne ENEL-MED S.A. concluded with companies from the General Group: Generali Życie Towarzystwo Ubezpieczeń S.A., Generali Towarzystwo Ubezpieczeń S.A., and Generali Powszechne Towarzystwo Emerytalne S.A. and General Finance Sp. z o.o. the agreement for the provision of medical services to employees, partners and their families. The agreement was concluded for indefinite period and its value during five years may reach about PLN 5,760,000.00. Until now, the cooperation between ENEL-MED S.A. and General involved the provision of medical services for customers of this insurance firm, who acquired health insurance policies. Since 1 November 2013, Generali will also offer pre-paid medical plans to its employees.

On 23 October 2013, Centrum Medyczne ENEL-MED S.A. signed an annex to the agreement concluding previously, which resulted in increasing the value of a long-term loan by PLN 5,000,000.00, for the purposes of partial repayment of loans bearing higher interest rates. Additionally, the loan incurred will allow partially replacing short-term financing with a long-term one, thus improving the debt structure.

Moreover, Enelbud Sp. z o.o., subsidiary of Centrum Medyczne ENEL-MED S.A. established a subsidiary Bonus Vitae Sp. z o.o. together with JH Group AG, with its registered office in St. Gallen (Swiss Confederation). This subsidiary will target clients from countries of the European Union. Enelbud holds 50% of shares in this newly established company. The company will offer long-term care for elderly people from Poland and from countries of the European Union.

On 6 November 2013, the Management Board of the Company announced the 3-year development strategy of the Company, which assumes improvement of the effectiveness of sales of pre-paid medical plans, together with extending business activity to Silesian and West Pomeranian markets, and – in line with increased utilisation of the potential – development of facilities in selected locations. In accordance with the strategy accepted, the Management Board of ENEL-MED also announced opening two new highly specialised profiled centres in Warsaw for individual customers, as well as the growth of the share of dentistry in the portfolio, *inter alia*, by a gradual increase in the number of dentist's surgeries. Activities in the area of long-term care for elderly people are a material part of the strategy.

17. INFORMATION ON CHANGES IN CONTINGENT LIABILITIES OR CONTINGENT ASSETS SINCE 31 DECEMBER 2012

Promissory note collateral for promissory notes issued by Centrum Medyczne Enel-Med Sp. z o.o. to secure liabilities due to leases to BFL Nieruchomości Sp. z o.o. amounted to PLN 9,083 thousand as at 30 September 2013 (PLN 9,373 thousand as at 31 December 2012).

Bank guarantees granted by Millennium Bank Credit Agricole Bank Polska SA to secure the correct performance of the agreement amounted to PLN 3,922 thousand as at 30 September 2013 (31 December 2012: PLN 3,639 thousand). The value of court cases against the Company was PLN 2,050 thousand as at 31 December 2012 and PLN 2,154 as at 30 September 2013.

As at 30 September 2013, the Company did not have any contingent assets.

(All amounts are stated in PLN'000 unless otherwise indicated)

18. OTHER INFORMATION THAT MIGHT HAVE A SIGNIFICANT IMPACT ON THE EVALUATION OF THE ECONOMIC AND FINANCIAL POSITION AS WELL AS THE FINANCIAL RESULT OF THE ISSUER

In the third quarter 2013, Centrum Medyczne ENEL-MED S.A. established a subsidiary under the name of Centrum Medyczne Diagnostyka Spółka z ograniczoną odpowiedzialnością (limited liability company). The Issuer took over 50 shares in this company, making up 100% of this company's share capital, and intends transferring to this company a part of assets that do not generate synergies with the core business of the Company, i.e. Bielany Diagnostic Centre in Warsaw, Magnetic Resonance Laboratory at Grunwaldzka Centre in Gdańsk, Magnetic Resonance Laboratory in Konin, Magnetic Resonance Laboratory in Mielec, Computed Tomography Laboratory in Poznań, Magnetic Resonance Laboratory in Łomża, Computed Tomography Laboratory in Wołomin and the Diagnostic Laboratory in Lublin.

The Company considers sale of the separated part of the enterprise, and funds obtained would be allocated for financing the implementation of the strategy presented.

(All amounts are stated in PLN'000 unless otherwise indicated)

OTHER NOTES TO THE CONDENSED QUARTERLY FINANCIAL STATEMENTS

1. Principles for drawing up condensed quarterly financial statements

Principles for drawing up condensed quarterly financial statements are described in the introduction to the condensed quarterly financial statements.

2. Description of the organisational structure of the Issuer's capital group, including the information on consolidated entities, and if the Issuer is a parent company that is not required by the law to or may not prepare consolidated financial statements, the information on the reason and legal basis for refraining from consolidation

Centrum Medyczne ENEL-MED S.A. is a part of the Capital Group, comprising Centrum Medyczne ENEL-MED S.A. as the parent company and subsidiaries: Enelbud Sp. z o.o. and Centrum Medyczne Diagnostyka Sp. z o.o.

Enelbud Sp. z o.o. was established in 2006 and is engaged in healthcare-related investments. It has experience and extensive knowledge of the requirements imposed on medical service providers and the conditions to be met by a property to be used for the purpose of medical activities. Centrum Medyczne ENEL-MED S.A. holds 80 shares in this subsidiary, which make up 80% of its share capital.

Centrum Medyczne Diagnostyka Sp. z o.o. was established in the third quarter of 2013. The Issuer took over 50 shares in this subsidiary, which make up 100% of its share capital. As at the date of publishing this report the subsidiary Centrum Medyczne Diagnostyka Sp. z o.o. does not carry out any operating activities. The planned core business of this company involves diagnostic imaging.

The Issuer did not draw up the consolidated financial statements as at 31 September 2013, based on the exemption provided for in Article 58 of the Accounting Act. The subsidiary is not covered by the consolidated financial statements, as the subsidiary's figures are insignificant for the purpose of providing a clear and fair picture of the Group's economic and financial position and its financial result.

3. Consequences of changes to the Issuer's structure, including as a result of a business combination, acquisition or sale of companies within the Issuer's Capital Group, long-term investments, split, restructuring and discontinuing the activities

On 30 August 2013, a subsidiary was established under the name of Centrum Medyczne Diagnostyka Sp. z o.o., with its registered office in Warsaw, in which Centrum Medyczne ENEL-MED S.A. took over 50 shares with a nominal value of PLN 100.00 each, i.e. shares with a total nominal value of PLN 5,000.00, making up 100% of this company's share capital. By the decision of 10 September 2013, the District Court for the capital city of Warsaw in Warsaw, 13th Business Department of the National Court Register registered the subsidiary under number KRS 0000475909.

As at the date of publishing this report the subsidiary Centrum Medyczne Diagnostyka Sp. z o.o. does not carry out any operating activities. The planned core business of this company involves diagnostic imaging.

4. Position of the Management Board with respect to the possibility of delivery of forecast results published for the particular year, in the light of the results presented in these quarterly financial statements in relation to the forecast results

The Company has not published its financial result forecasts for 2013.

(All amounts are stated in PLN'000 unless otherwise indicated)

5. Information on shareholders holding at least 5% of the number of votes at the general meeting of shareholders, directly or indirectly through subsidiaries

The table below presents shareholders holding at least 5% of total votes at the annual general meeting of shareholders of Centrum Medyczne ENEL-MED S.A. as at the date of submitting the quarterly report.

Shareholder	Number of shares	% of the capital	Number of votes	% of votes
Adam Rozwadowski*	7,124,000	30.23%	7,124,000	30.23%
Anna Rozwadowska**	7,123,950	30.23%	7,123,950	30.23%
Generali Otwarty Fundusz Emerytalny	2,377,000	10.09%	2,377,000	10.09%
Otwarty Fundusz Emerytalny PZU "Złota Jesień" and Dobrowolny Fundusz Emerytalny PZU	1,400,000	5.94%	1,400,000	5.94%

^{*} Through Koremia Investments Ltd. with its registered office in the Republic of Cyprus, in which Adam Rozwadowski holds 100% of shares.

The number of shares held by Otwarty Fundusz Emerytalny PZU "Złota Jesień" has changed since the date of submitting the last periodic report. In accordance with the list of persons entitled to participate in the Annual General Meeting of Shareholders convened for 2 October 2012, received from the National Depository for Securities, Otwarty Fundusz Emerytalny PZU "Złota Jesień" increased the number of shares held and votes at the general meeting of shareholders from 1,186,229, making up 5.03% of the Company's capital and 5.03% of votes, to 1,400,000 shares and votes at the general meeting of shareholders, making up 5.94% of the Company's share capital and number of votes at the general meeting of shareholders.

6. Information on shares of the Issuer held by members of management and supervisory authorities

The table below presents shares of Centrum Medyczne ENEL-MED S.A. held by members of the Management Board and Supervisory Board of the Company as at the date of submitting the quarterly report.

Shareholder	Number of shares	% of the capital	Number of votes	% of votes
Adam Rozwadowski*	7,124,000	30.23%	7,124,000	30.23%
Anna Rozwadowska**	7,123,950	30.23%	7,123,950	30.23%
Jacek Rozwadowski***	992,800	4.21%	992,800	4.21%

^{*} Adam Rozwadowski, President of the Management Board holds 100% of shares in Koremia Investments Ltd., with its registered office in the Republic of Cyprus, which is a shareholder of Centrum Medyczne ENEL-MED S.A.

The number of shares or rights to shares in the Issuer held by members of management and supervisory authorities has not changed since the publication of the previous periodic report, i.e. the report for the first half of 2013.

^{**} Through Versinus Ltd., with its registered office in the Republic of Cyprus, in which Anna Rozwadowska holds 100% of shares.

^{**} Anna Rozwadowska, Chairman of the Supervisory Board holds 100% of shares in Versinus Ltd., with its registered office in the Republic of Cyprus, which is a shareholder of Centrum Medyczne ENEL-MED S.A.

^{***} Jacek Rozwadowski, Vice President of the Management Board holds 100% of shares in Smerona Holdings Ltd., with its registered office in the Republic of Cyprus, which is a shareholder of Centrum Medyczne ENEL-MED S.A.

(All amounts are stated in PLN'000 unless otherwise indicated)

7. Information on proceedings at court, before arbitration tribunal or public administration body with respect to liabilities and receivables

As at date of publishing of the quarterly report, the Company and its subsidiary did not participate in any proceedings at court, before arbitration tribunal or public administration body with respect to liabilities and receivables of the Company or its subsidiary, the value of which would be equivalent to at least 10% of its equity.

Total value of all claims subject to proceedings pertaining to liabilities, pending as at the date of publishing the quarterly report, did not exceed 10% of the Issuer's equity.

Total value of all claims subject to all proceedings pertaining to debts, pending as at the date of publishing the quarterly report, did not exceed 10% of the Issuer's equity too.

Information on related-party transaction or transactions concluded by the Issuer or its subsidiary, which is or are material and was or were concluded on terms other than an arm's length basis

In the third quarter 2013, neither the Company nor its subsidiary concluded any material related-party transactions on terms other than an arm's length basis.

9. Information on the Issuer or its subsidiary granting a surety for loans or borrowings, or granting a guarantee, equalled at least 10% of the Issuer's equity

The Company has not granted any surety for loans or borrowings and has not granted any guarantee to another entity, for the value equalled at least 10% of the Issuer's equity.

Centrum Medyczne Diagnostyka Sp. z o.o., subsidiary of the Issuer, granted the guarantee to Bank Millennium S.A. for liabilities of Centrum Medyczne ENEL-MED S.A., for the amount of PLN 9,600,000. In the case of sale of shares in Centrum Medyczne Diagnostyka Sp. z o.o. this guarantee will automatically expire. Centrum Medyczne Diagnostyka Sp. z o.o. is a subsidiary of Centrum Medyczne ENEL-MED S.A. It was established in the third quarter of 2013, and the Issuer took over 50 shares in this subsidiary, which make up 100% of its share capital.

10. Information on factors that in the opinion of the Company would impact its results in the perspective of at least next quarter

The Company has concluded other agreements with corporate clients, including, *inter alia*, the National Bank of Poland or Raiffeisen Bank Polska. The agreement with the National Bank of Poland, increasing the previous value of pre-paid medical plans while extending the scope of services, was concluded for 24 months with an option to extend it by the National Bank of Poland for additional 12 months. The value of this agreement depends on the number of persons covered by pre-paid medical plans, and might reach about PLN 7,588,992.00 gross for 24 months. At the same time, the annex to the agreement with Raiffeisen Bank Polska has added about 3,000 employees of Polbank (the company acquired by Raiffeisen Bank Polska) and their families to the group of persons covered by pre-paid medical plans. The annex to the agreement was concluded for 17 months without an early termination option, with an option to automatically extend it for the next 19 months, and its value depends on the number of persons covered by pre-paid medical plans, and might reach about PLN 6,455,462.00 for 17 months.

Additionally, in October 2013, the Company concluded with companies from the General Group: Generali Życie Towarzystwo Ubezpieczeń S.A., Generali Towarzystwo Ubezpieczeń S.A., and Generali Powszechne Towarzystwo Emerytalne S.A. and General Finance Sp. z o.o. the agreement for the provision of medical services to employees, partners and their families. The agreement was concluded for indefinite period and its value during five years may reach about PLN 5,760,000.00. Until now, the cooperation between ENEL-MED S.A. and General involved the provision of medical services for customers of this insurance firm, who acquired health insurance policies. Since 1 November 2013, Generali will also offer pre-paid medical plans to its employees. Agreements concluded can support the growth in the Company's revenues from the provision of services in subsequent quarters.

(All amounts are stated in PLN'000 unless otherwise indicated)

Moreover, the Company incurred a long-term loans for PLN 5,000,000.00, which will be used to repay loans bearing higher interest rates. Additionally, the loan incurred will allow partially replacing short-term financing with a long-term one, thus improving the debt structure.

Furthermore, the Company signed the annex to the space lease agreement for the purposes of the multi-profile outpatient clinic in Poznań. The annex has reduced lease costs by PLN 500,000.00 in 2013.